摘要
目的 观察罗沙司他治疗血液透析肾性贫血患者的疗效及安全性。方法 选取2019年8月至2021年8月我院肾内科收治的血液透析肾性贫血患者60例为研究对象,采取随机数字表法将其分为3组,每组20例。A组采用小剂量重组人促红细胞生成素(EPO)皮下注射,B组采用大剂量EPO皮下注射,C组采用罗沙司他胶囊口服。分别检测并比较三组患者治疗前、治疗4周、治疗12周的血红蛋白(HB)、红细胞压积(HCT)、血清铁蛋白(FER)及血压(BP)变化;治疗过程中,密切观察并记录患者不良反应发生情况。结果 治疗前,三组患者HB、HCT、FER及BP比较差异无统计学意义(P>0.05)。治疗4周,B组和C组HB、HCT均高于治疗前,且C组均高于A组、B组,B组高于A组(P<0.05);治疗12周,三组HB、HCT均高于治疗前,且C组均高于A组,B组均高于A组(P<0.05);B组与C组比较差异无统计学意义(P>0.05)。治疗4、12周,三组FER比较差异无统计学意义(P>0.05);但C组治疗12周,FER较治疗前降低(P<0.05)。治疗4周,三组BP比较差异无统计学意义(P>0.05);治疗12周,B组BP高于A组及C组(P<0.05);A组与C组BP比较差异无统计学意义(P>0.05)。所有患者均未出现治疗中断、治疗延迟及治疗引起的相关死亡。A组、B组、C组不良反应发生率分别为20%、30%、20%,差异无统计学意义(P>0.05),经积极治疗能有效缓解。结论 罗沙司他治疗血液透析肾性贫血患者疗效较好,且起效较快,同时对血清铁蛋白依赖不高,且安全性与EPO无差异。
Objective To observe the efficacy and safety of roxadustat in patients with renal anemia on hemodialysis.Methods A total of 60 patients with renal anemia on hemodialysis admitted to the Department of Nephrology of our hospital from August 2019 to August 2021 were selected as the study subjects.They were divided into three groups(A,B,C) by random number table method, with 20 patients in each group.Among them, group A received low dose of recombinant human erythropoietin(EPO) by subcutaneous infection, group B received high dose of EPO by subcutaneous, and group C received roxadustat orally.The changes of hemoglobin(HB),hematocrit(HCT),serum ferritin(FER)and blood pressure(BP)in 3 groups before treatment, 4 weeks after treatment and 12 weeks after treatment were detected and compared.During the treatment, the occurrence of adverse reactions in patients was closely observed and recorded.Results Before treatment, there were no significant differences in HB,HCT,FER or BP among 3 groups(P>0.05).After 4 weeks of treatment, HB and HCT in group B and C were higher, group C was higher than group A and group B,and group B was higher than group A(P<0.05);after 12 weeks of treatment, HB and HCT in the three groups were higher, group C was higher than group A,and group B was higher than group A(P<0.05).There was no significant difference between group B and group C(P>0.05).After 4 weeks and 12 weeks of treatment, there was no difference in FER among the three groups(P>0.05);FER in group C was lower after 12 weeks of treatment(P<0.05).After 4 weeks of treatment, there was no significant difference in BP among the three groups(P>0.05);after 12 weeks of treatment, the BP of group B was higher than that of group A and group C(P<0.05).There was no significant difference in BP between group A and group C(P>0.05).During the treatment, no treatment interruption, treatment delay or treatment-related death occurred in all patients, and there was effective alleviation after active treatment.The incidence rates of adverse reactions in gro
作者
蒋飞飞
洪大情
杜亚琴
甘措
陈琴
关欣
邓菲
Jiang Feifei;Hong Daqing;Du Yaqin;Gan Cuo;Chen Qin;Guan Xin;Deng Fei(Department of Nephrology,Jinniu District People′s Hospital,Jinniu Hospital of Sichuan Provincial People′s Hospital,Chengdu 610036,China;Department of Nephrology,Sichuan Provincial People′s Hospital,Affiliated Hospital of University of Electronic Science and Technology,Chengdu 610072,China)
出处
《实用药物与临床》
CAS
2022年第11期1008-1011,共4页
Practical Pharmacy and Clinical Remedies
基金
四川省科研基金专项科研课题(2021HR16)
成都市医学科研课题(2020208)
成都市金牛区科研资助项目(JNQN20-05)
成都市金牛区科研资助项目(JNZD20-14)。
